Gang Lin

List of Publications by Year
in descending order

31	1,571	430874	454955
papers	citations	18 h-index	30 g-index

32	32	32	1527
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 9350-9375.	6.4	8
2	Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Antiâ€malaria Activity in Humanized Mice. Angewandte Chemie - International Edition, 2021, 60, 9279-9283.	13.8	20
3	Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Antiâ€malaria Activity in Humanized Mice. Angewandte Chemie, 2021, 133, 9365-9369.	2.0	2
4	Noncytotoxic Inhibition of the Immunoproteasome Regulates Human Immune Cells In Vitro and Suppresses Cutaneous Inflammation in the Mouse. Journal of Immunology, 2021, 206, 1631-1641.	0.8	9
5	Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome. Journal of Medicinal Chemistry, 2021, 64, 6262-6272.	6.4	9
6	Microbial proteasomes as drug targets. PLoS Pathogens, 2021, 17, e1010058.	4.7	14
7	Structureâ€“Activity Relationships of Noncovalent Immunoproteasome Î²5i-Selective Dipeptides. Journal of Medicinal Chemistry, 2020, 63, 13103-13123.	6.4	10
8	Activity of Epigenetic Inhibitors against Plasmodium falciparum Asexual and Sexual Blood Stages. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	21
9	Immunoproteasome inhibitor DPLG3 attenuates experimental colitis by restraining NF-ÎºB activation. Biochemical Pharmacology, 2020, 177, 113964.	4.4	13
10	Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome. Journal of Medicinal Chemistry, 2019, 62, 9246-9253.	6.4	14
11	Improvement of Asparagine Ethylenediamines as Anti-malarial Plasmodium-Selective Proteasome Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 6137-6145.	6.4	28
12	Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6863-E6870.	7.1	71
13	Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome. ACS Infectious Diseases, 2017, 3, 176-181.	3.8	19
14	Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome. Biochemistry, 2017, 56, 324-333.	2.5	14
15	Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes. Nature Communications, 2017, 8, 1692.	12.8	45
16	Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8425-E8432.	7.1	54
17	Immunoproteasome Î²5iâ€Selective Dipeptidomimetic Inhibitors. ChemMedChem, 2016, 11, 2127-2131.	3.2	26
18	Stressed Mycobacteria Use the Chaperone ClpB to Sequester Irreversibly Oxidized Proteins Asymmetrically Within and Between Cells. Cell Host and Microbe, 2015, 17, 178-190.	11.0	104

#	Article	IF	Citations
19	Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome. ACS Medicinal Chemistry Letters, 2014, 5, 405-410.	2.8	42
20	Bacterial Proteasome. , 2013, , 3671-3677.		0
21	N,C-Capped Dipeptides with Selectivity for Mycobacterial Proteasome over Human Proteasomes: Role of S3 and S1 Binding Pockets. Journal of the American Chemical Society, 2013, 135, 9968-9971.	13.7	54
22	Structural basis for the assembly and gate closure mechanisms of the Mycobacterium tuberculosis 20S proteasome. EMBO Journal, 2010, 29, 2037-2047.	7.8	38
23	Fellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasome. Archives of Biochemistry and Biophysics, 2010, 501, 214-220.	3.0	57
24	Structural Insights on the Mycobacterium tuberculosis Proteasomal ATPase Mpa. Structure, 2009, 17, 1377-1385.	3.3	65
25	Inhibitors selective for mycobacterial versus human proteasomes. Nature, 2009, 461, 621-626.	27.8	213
26	A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis. Tuberculosis, 2008, 88, S25-S33.	1.9	52
27	Selective Killing of Nonreplicating Mycobacteria. Cell Host and Microbe, 2008, 3, 137-145.	11.0	180
28	Distinct Specificities of Mycobacterium tuberculosis and Mammalian Proteasomes for N-Acetyl Tripeptide Substrates. Journal of Biological Chemistry, 2008, 283, 34423-34431.	3.4	51
29	Mycobacterium tuberculosis prcBAgenes encode a gated proteasome with broad oligopeptide specificity. Molecular Microbiology, 2006, 59, 1405-1416.	2.5	98
30	Structure of theMycobacterium tuberculosisproteasome and mechanism of inhibition by a peptidyl boronate. Molecular Microbiology, 2006, 59, 1417-1428.	2.5	120
31	Characterization of a Mycobacterium tuberculosis proteasomal ATPase homologue. Molecular Microbiology, 2004, 55, 561-571.	2.5	119